Due to the immunogenicity of ccRCC and good response rate, the FDA has already approved nivolumab in 2015 [19], an immune checkpoint inhibitor targeting PD-1, to treat RCC, followed by the approval of the combination therapies of nivolumab and ipilimumab [20], as well as pembrolizumab (anti-PD-1) or avelumab (anti-PD-L1) with axitinib (VEGF receptor tyrosine kinase inhibitor) [21]. The gene discussed is CD274; the disease is nonpapillary renal cell carcinoma.